Samuel L. Aitken, PharmD, MPH, BCIDP

home / authors / samuel-l-aitken-pharmd-mph-bcidp

Aitken is a clinical pharmacist specialist in Infectious Diseases at Michigan Medicine with a practice focused primarily on immunocompromised hosts. He is a co-author on both editions of the IDSA guidance documents on the treatment of infections caused by gram-negative bacteria.

Articles

NDM-Producing E coli Harboring PBP Insert Variants Emerges as New Threat

Raneem H. Pallotta, PharmD;Samuel L. Aitken, PharmD, MPH, BCIDP

August 28th 2024

As with other metallo-β-lactamases, NDM is capable of hydrolyzing nearly all β-lactams, including carbapenems, and the search for the proper antimicrobials is challenging.

Updates to Multidrug Resistance Guidance

Samuel L. Aitken, PharmD, MPH, BCIDP

February 23rd 2022

The 2019 Strategic Plan of the Infectious Diseases Society of America lays the groundwork for understanding prescribing practices.

Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens

Sarah L. Spitznogle, PharmD*;Samuel L. Aitken, PharmD, MPH, BCIDP

October 14th 2019

Novel β-lactam/β-lactamase inhibitor combinations and cefiderocol may play a part in the treatment of infections caused by Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cepacia complex.